CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies.

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover ...

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...